Skip to content
Accessibility help

Search NICE…

Skip to content

Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About

Search results

Skip to results

Area of interest

Area of interestAntimicrobial prescribing (42)COVID-19 (33)

Type

TypeGuidance (3905)Indicators (274)News (248)NICE advice (496)Quality standards (254)Research recommendations (1918)

Status

StatusAwaiting development (338)Discontinued (410)In consultation (5)In development (388)Published (2468)Topic selection (287)

Last updated

Last updatedLast 3 months (77)Last 6 months (138)Last year (581)Last 3 years (1656)

Guidance programme

Guidance programmeAntimicrobial prescribing guidelines (25)Cancer service guidelines (10)Clinical guidelines (381)COVID-19 NHSE/I specialty guides (2)COVID-19 rapid guidelines (27)Diagnostics guidance (93)Health technology evaluations (45)Highly specialised technologies guidance (48)Interventional procedures guidance (953)Medical technologies guidance (152)Medicines practice guidelines (5)NICE guidelines (562)Public health guidelines (88)Safe staffing guidelines (7)Social care guidelines (47)Technology appraisal guidance (2048)

Advice programme

Advice programmeCOVID-19 rapid summaries (8)Evidence summaries (172)Medtech innovation briefings (324)

Showing 7381 to 7395 of 7708 results

Sort by

Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251]
Discontinued [GID-TA10525]
Result type
Technology appraisal guidance
Status
Discontinued
Ibrutinib for untreated mantle cell lymphoma [ID1221]
Discontinued [GID-TA10185]
Result type
Technology appraisal guidance
Status
Discontinued
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565
Discontinued [GID-TA10502]
Result type
Technology appraisal guidance
Status
Discontinued
Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]
Discontinued [GID-TA11255]
Result type
Technology appraisal guidance
Status
Discontinued
Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]
Discontinued [GID-TA10929]
Result type
Technology appraisal guidance
Status
Discontinued
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]
Discontinued [GID-TA11204]
Result type
Technology appraisal guidance
Status
Discontinued
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]
Discontinued [GID-TA10848]
Result type
Technology appraisal guidance
Status
Discontinued
Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]
Discontinued [GID-TA10861]
Result type
Technology appraisal guidance
Status
Discontinued
Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]
Discontinued [GID-TA10996]
Result type
Technology appraisal guidance
Status
Discontinued
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]
Discontinued [GID-TA10995]
Result type
Technology appraisal guidance
Status
Discontinued
Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]
Discontinued [GID-TA11108]
Result type
Technology appraisal guidance
Status
Discontinued
Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]
Discontinued [GID-TA10937]
Result type
Technology appraisal guidance
Status
Discontinued
Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]
Discontinued [GID-TA10965]
Result type
Technology appraisal guidance
Status
Discontinued
Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]
Discontinued [GID-TA10863]
Result type
Technology appraisal guidance
Status
Discontinued
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]
Discontinued [GID-TA10766]
Result type
Technology appraisal guidance
Status
Discontinued

Previous page
1
…
491
492
Current page 493
494
495
…
514
Page 493 of 514
Next page

Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Knowledge resources

About NICE
Into practice
Get involved with NICE
Jobs
News
Newsletters and alerts
Contact us
Leave feedback
Reusing our content
NICE UK Open Content Licence
Syndicate our content
Events

Facebook
X
YouTube
LinkedIn

Accessibility
Freedom of information
Glossary
Terms and conditions
Privacy notice
Cookies

© NICE 2024. All rights reserved. Subject to Notice of rights.